Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects

World Journal of Gastroenterology

Volumn 20, Issue 24, 2014, Pages 7830-7848

  Neureiter, Daniel ^a   Jäger, Tarkan ^a   Ocker, Matthias ^b   Kiesslich, Tobias ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b BAYER PHARMA AG   (Germany)

Author keywords

DNA methylation; Epigenetics; Epithelial mesenchymal transition; Histone modification; Pancreatic cancer; Targeted therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; BORTEZOMIB; CAPECITABINE; CELECOXIB; CURCUMIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DNA METHYLTRANSFERASE; EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; ENTINOSTAT; FLUOROURACIL; GEMCITABINE; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HEPATOCYTE NUCLEAR FACTOR 3BETA; HISTONE DEACETYLASE INHIBITOR; ISOTRETINOIN; MICRORNA 196A; MICRORNA 218; PANOBINOSTAT; POLYCOMB GROUP PROTEIN; PROTEIN P16; RING FINGER PROTEIN; SALINOSPORAMIDE A; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX3; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VORINOSTAT; ZEBULARINE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETIC REPRESSION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE TARGETING; GENETIC ASSOCIATION; HISTONE ACETYLATION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; MUTATION; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS CANCER; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG DESIGN; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PHENOTYPE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PHENOTYPE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84903144996     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i24.7830     Document Type: Article

References (239)

1. Ma J, Siegel R, Jemal A. Pancreatic cancer death rates by race among US men and women, 1970-2009. J Natl Cancer Inst 2013; 105: 1694-1700 [PMID: 24203988 DOI: 10.1093/jnci/ djt292]
2. Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013; 62: 317-326 [PMID: 23112132 DOI: 10.1136/gutjnl-2012-303588]
3. Li D, Abbruzzese JL. New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res 2010; 16: 4313-4318 [PMID: 20647474 DOI: 10.1158/1078-0432.CCR-09-1942]
4. Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 2012; 18: 1565-1572 [PMID: 22529684 DOI: 10.3748/wjg.v18.i14.1565]
5. Kim SC, Kim YH, Park KM, Lee YJ. Pancreatic cancer surgery: the state of the art. Curr Drug Targets 2012; 13: 764-771 [PMID: 22458522]
6. Jarboe J, Saif MW. First line therapy for metastatic pancreatic cancer. JOP 2013; 14: 340-343 [PMID: 23846923 DOI: 10.6092/1590-8577/1667]
7. Carpelan-Holmström M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G, Haglund C. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005; 54: 385-387 [PMID: 15710987 DOI: 10.1136/gut.2004.047191]
8. McCleary-Wheeler AL, Lomberk GA, Weiss FU, Schneider G, Fabbri M, Poshusta TL, Dusetti NJ, Baumgart S, Iovanna JL, Ellenrieder V, Urrutia R, Fernandez-Zapico ME. Insights into the epigenetic mechanisms controlling pancreatic carcino-genesis. Cancer Lett 2013; 328: 212-221 [PMID: 23073473 DOI: 10.1016/j.canlet.2012.10.005]
9. Kiesslich T, Berr F, Alinger B, Kemmerling R, Pichler M, Ocker M, Neureiter D. Current status of therapeutic targeting of developmental signalling pathways in oncology. Curr Pharm Biotechnol 2012; 13: 2184-2220 [PMID: 21605074]
10. Quint K, Stintzing S, Alinger B, Hauser-Kronberger C, Dietze O, Gahr S, Hahn EG, Ocker M, Neureiter D. The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. Pancreatology 2009; 9: 116-126 [PMID: 19077462 DOI: 10.1159/000178882]
11. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBO-CAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
12. Jemal A, Bray F, Center M M, Ferlay J, Ward E, Forman D, Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
13. American Society of Clinical Oncology (ASCO): Cancer.Net. Accessed Nov 27, 2013. Available from: URL: http://www.cancer.net/cancer-types/pancreatic-cancer/statistics.
14. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008; 247: 456-462 [PMID: 18376190 DOI: 10.1097/ SLA.0b013e3181613142]
15. Lüttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Klöp-pel G. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immuno-histochemical assessment of proliferation. J Pathol 2000; 191: 154-161 [PMID: 10861575]
16. Klöppel G, Lingenthal G, von Bülow M, Kern HF. Histologi-cal and fne structural features of pancreatic ductal adenocar-cinomas in relation to growth and prognosis: studies in xe-nografted tumours and clinico-histopathological correlation in a series of 75 cases. Histopathology 1985; 9: 841-856 [PMID: 2997015]
17. Giovinazzo F, Turri G, Zanini S, Butturini G, Scarpa A, Bassi C. Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma. Surg Oncol 2012; 21: e171-e182 [PMID: 22981281 DOI: 10.1016/j.suronc.2012.07.004]
18. Adsay NV, Basturk O, Bonnett M, Kilinc N, Andea AA, Feng J, Che M, Aulicino MR, Levi E, Cheng JD. A proposal for a new and more practical grading scheme for pancreatic ductal adenocarcinoma. Am J Surg Pathol 2005; 29: 724-733 [PMID: 15897739]
19. Karamitopoulou E. Role of Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Is Tumor Budding the Missing Link? Front Oncol 2013; 3: 221 [PMID: 24062980 DOI: 10.3389/fonc.2013.00221]
20. Handra-Luca A, Hong SM, Walter K, Wolfgang C, Hruban R, Goggins M. Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas. Br J Cancer 2011; 104: 1296-1302 [PMID: 21448168 DOI: 10.1038/bjc.2011.93]
21. Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJ, Jian KY, Huang SS, Jiang SS, Shan YS, Lin PW, Shen YY, Lee MT, Chan TS, Chang CC, Chen CH, Chang IS, Lee YL, Chen LT, Tsai KK. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression. Gastroenterology 2013; 145: 1110-1120 [PMID: 23896173 DOI: 10.1053/j.gastro.2013.07.040]
22. Hruban RH, Adsay NV. Molecular classification of neoplasms of the pancreas. Hum Pathol 2009; 40: 612-623 [PMID: 19362631 DOI: 10.1016/j.humpath.2009.01.008]
23. Wilentz RE, Goggins M, Redston M, Marcus VA, Adsay NV, Sohn TA, Kadkol SS, Yeo CJ, Choti M, Zahurak M, Johnson K, Tascilar M, Offerhaus GJ, Hruban RH, Kern SE. Genetic, Immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol 2000; 156: 1641-1651 [PMID: 10793075 DOI: 10.1016/S0002-9440(10)65035-3]
24. Zamboni G, Hirabayashi K, Castelli P, Lennon AM. Pre-cancerous lesions of the pancreas. Best Pract Res Clin Gastroenterol 2013; 27: 299-322 [PMID: 23809247 DOI: 10.1016/ j.bpg.2013.04.001]
25. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012; 22: 9-20 [PMID: 22789535 DOI: 10.1016/j.ccr.2012.06.008]
26. Breitkreutz D, Hlatky L, Rietman E, Tuszynski JA. Molecular signaling network complexity is correlated with cancer patient survivability. Proc Natl Acad Sci USA 2012; 109: 9209-9212 [PMID: 22615392 DOI: 10.1073/pnas.1201416109]
27. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikols-kaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806 [PMID: 18772397 DOI: 10.1126/sci-ence.1164368]
28. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP. Exomic sequencing identifes PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217 [PMID: 19264984 DOI: 10.1126/science.1171202]
29. Ueki T, Toyota M, Skinner H, Walter KM, Yeo CJ, Issa JP, Hruban RH, Goggins M. Identifcation and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 2001; 61: 8540-8546 [PMID: 11731440]
30. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63: 3735-3742 [PMID: 12839967]
31. Hong SM, Park JY, Hruban RH, Goggins M. Molecular signatures of pancreatic cancer. Arch Pathol Lab Med 2011; 135: 716-727 [PMID: 21631264 DOI: 10.1043/2010-0566-RA.1]
32. Yamamoto H, Itoh F, Nakamura H, Fukushima H, Sasaki S, Perucho M, Imai K. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread mic-rosatellite instability. Cancer Res 2001; 61: 3139-3144 [PMID: 11306499]
33. Nakata B, Wang YQ, Yashiro M, Nishioka N, Tanaka H, Ohi-ra M, Ishikawa T, Nishino H, Hirakawa K. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res 2002; 8: 2536-2540 [PMID: 12171881]
34. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, Gog-gins M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60: 1835-1839 [PMID: 10766168]
35. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70 [PMID: 10647931]
36. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
37. Gnoni A, Licchetta A, Scarpa A, Azzariti A, Brunetti AE, Simone G, Nardulli P, Santini D, Aieta M, Delcuratolo S, Silvestris N. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci 2013; 14: 19731-19762 [PMID: 24084722 DOI: 10.3390/ijms141019731]
38. Holliday R. The inheritance of epigenetic defects. Science 1987; 238: 163-170 [PMID: 3310230]
39. Grzenda A, Ordog T, Urrutia R. Polycomb and the emerging epigenetics of pancreatic cancer. J Gastrointest Cancer 2011; 42: 100-111 [PMID: 21336826 DOI: 10.1007/s12029-011-9262-4]
40. Lomberk GA. Epigenetic silencing of tumor suppressor genes in pancreatic cancer. J Gastrointest Cancer 2011; 42: 93-99 [PMID: 21318291 DOI: 10.1007/s12029-011-9256-2]
41. Antequera F, Bird A. CpG islands as genomic footprints of promoters that are associated with replication origins. Curr Biol 1999; 9: R661-R667 [PMID: 10508580]
42. Cheng X, Blumenthal RM. Mammalian DNA methyltrans-ferases: a structural perspective. Structure 2008; 16: 341-350 [PMID: 18334209 DOI: 10.1016/j.str.2008.01.004]
43. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92 [PMID: 6185846]
44. Esteller M. Cancer epigenomics: DNA methylomes and his-tone-modifcation maps. Nat Rev Genet 2007; 8: 286-298 [PMID: 17339880 DOI: 10.1038/nrg2005]
45. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159 [PMID: 18337604 DOI: 10.1056/NEJMra072067]
46. Strahl BD, Allis CD. The language of covalent histone modifcations. Nature 2000; 403: 41-45 [PMID: 10638745 DOI: 10.1038/47412]
47. Kornberg RD, Lorch Y. Twenty-fve years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999; 98: 285-294 [PMID: 10458604]
48. Cosgrove MS, Boeke JD, Wolberger C. Regulated nucleo-some mobility and the histone code. Nat Struct Mol Biol 2004; 11: 1037-1043 [PMID: 15523479 DOI: 10.1038/nsmb851]
49. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080 [PMID: 11498575 DOI: 10.1126/sci-ence.1063127]
50. Bojang P, Ramos KS. The promise and failures of epigenetic therapies for cancer treatment. Cancer Treat Rev 2014; 40: 153-169 [PMID: 23831234 DOI: 10.1016/j.ctrv.2013.05.009]
51. Koutsounas I, Giaginis C, Patsouris E, Theocharis S. Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol 2013; 19: 813-828 [PMID: 23430136 DOI: 10.3748/wjg.v19.i6.813]
52. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med 2010; 16: 257-267 [PMID: 20493775]
53. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer-new paradigms in molecular oncology. Curr Opin Cell Biol 2009; 21: 470-479 [PMID: 19411171]
54. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233 [PMID: 19167326 DOI: 10.1016/j.cell.2009.01.002]
55. Shukla GC, Singh J, Barik S. MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol 2011; 3: 83-92 [PMID: 22468167]
56. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, Bartel DP. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005; 310: 1817-1821 [PMID: 16308420 DOI: 10.1126/sci-ence.1121158]
57. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumori-genesis and cell death. Oncogene 2008; 27: 5959-5974 [PMID: 18836476]
58. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34: D140-D144 [PMID: 16381832 DOI: 10.1093/nar/gkj112]
59. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105 [PMID: 18955434 DOI: 10.1101/gr.082701.108]
60. Xi JJ. MicroRNAs in Cancer. Cancer Treat Res 2013; 158: 119-137 [PMID: 24222356 DOI: 10.1007/978-3-642-31659-3_5]
61. Melo SA, Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res 2012; 18: 4234-4239 [PMID: 22711704 DOI: 10.1158/1078-0432.CCR-11-2010]
62. Perera RJ, Ray A. Epigenetic regulation of miRNA genes and their role in human melanomas. Epigenomics 2012; 4: 81-90 [PMID: 22332660 DOI: 10.2217/epi.11.114]
63. Agirre X, Martínez-Climent JÁ, Odero MD, Prósper F. Epigenetic regulation of miRNA genes in acute leukemia. Leukemia 2012; 26: 395-403 [PMID: 22143672 DOI: 10.1038/ leu.2011.344]
64. Gros C, Fahy J, Halby L, Dufau I, Erdmann A, Gregoire JM, Ausseil F, Vispé S, Arimondo PB. DNA methylation inhibitors in cancer: recent and future approaches. Biochi-mie 2012; 94: 2280-2296 [PMID: 22967704 DOI: 10.1016/ j.biochi.2012.07.025]
65. Peedicayil J. The role of DNA methylation in the pathogen-esis and treatment of cancer. Curr Clin Pharmacol 2012; 7: 333-340 [PMID: 22794162]
66. Mikeska T, Bock C, Do H, Dobrovic A. DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn 2012; 12: 473-487 [PMID: 22702364 DOI: 10.1586/erm.12.45]
67. Orr JA, Hamilton PW. Histone acetylation and chromatin pattern in cancer. A review. Anal Quant Cytol Histol 2007; 29: 17-31 [PMID: 17375871]
68. Shukla V, Vaissière T, Herceg Z. Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res 2008; 637: 1-15 [PMID: 17850830 DOI: 10.1016/ j.mrfmmm.2007.07.012]
69. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005; 25: 261-309 [PMID: 15717297 DOI: 10.1002/med.20024]
70. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkühler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 2007; 17: 195-211 [PMID: 17325692 DOI: 10.1038/sj.cr.7310149]
71. Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta 2011; 1815: 75-89 [PMID: 20951770 DOI: 10.1016/ j.bbcan.2010.10.002]
72. Decarlo D, Hadden MK. Oncoepigenomics: making histone lysine methylation count. Eur J Med Chem 2012; 56: 179-194 [PMID: 22975593 DOI: 10.1016/j.ejmech.2012.08.010]
73. Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P, Zi X. Histone lysine-specifc methyltransfer-ases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets 2013; 13: 558-579 [PMID: 23713993]
74. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013; 774: 1-20 [PMID: 23377965 DOI: 10.1007/978-94-007-5590-1_1]
75. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 2013; 329: 125-136 [PMID: 23196059 DOI: 10.1016/j.canlet.2012.11.001]
76. Hoshino I, Matsubara H. MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today 2013; 43: 467-478 [PMID: 23129027 DOI: 10.1007/s00595-012-0392-5]
77. Zhu Y, Zhang JJ, Zhu R, Zhu Y, Liang WB, Gao WT, Yu JB, Xu ZK, Miao Y. The increase in the expression and hypo-methylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Med Oncol 2011; 28 Suppl 1: S175-S184 [PMID: 20922503 DOI: 10.1007/s12032-010-9683-0]
78. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayas-hi H, Iacobuzio-Donahue CA, Rosty C, Goggins M. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003; 63: 4158-4166 [PMID: 12874021]
79. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, Smyrk TC, Chari ST, Urrutia R, Billadeau DD. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005; 7: 39-49 [PMID: 15652748 DOI: 10.1016/j.ccr.2004.11.024]
80. He S, Wang F, Yang L, Guo C, Wan R, Ke A, Xu L, Hu G, Xu X, Shen J, Wang X. Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer. PLoS One 2011; 6: e27684 [PMID: 22110720 DOI: 10.1371/journal.pone.0027684]
81. Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 2010; 70: 2115-2125 [PMID: 20160041 DOI: 10.1158/0008-5472.CAN-09-2979]
82. Yamada N, Nishida Y, Tsutsumida H, Hamada T, Goto M, Higashi M, Nomoto M, Yonezawa S. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 mod-ifcation in cancer cells. Cancer Res 2008; 68: 2708-2716 [PMID: 18413738 DOI: 10.1158/0008-5472.CAN-07-6844]
83. Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M, Yonezawa S. MUC2 expression is regulated by histone H3 modifcation and DNA methylation in pancreatic cancer. Int J Cancer 2006; 119: 1850-1857 [PMID: 16721789 DOI: 10.1002/ijc.22047]
84. Yamada N, Nishida Y, Yokoyama S, Tsutsumida H, Houjou I, Kitamoto S, Goto M, Higashi M, Yonezawa S. Expression of MUC5AC, an early marker of pancreatobiliary cancer, is regulated by DNA methylation in the distal promoter region in cancer cells. J Hepatobiliary Pancreat Sci 2010; 17: 844-854 [PMID: 20734208 DOI: 10.1007/s00534-010-0278-0]
85. Fritsche P, Seidler B, Schüler S, Schnieke A, Göttlicher M, Schmid RM, Saur D, Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009; 58: 1399-1409 [PMID: 19528037 DOI: 10.1136/gut.2009.180711]
86. Ouaïssi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, Lafontaine JS, Payan MJ, Dahan L, Pirrò N, Seitz JF, Mas E, Lombardo D, Ouaissi A. High histone deacetylase 7 (HDAC7) expression is signifcantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 2008; 15: 2318-2328 [PMID: 18506539 DOI: 10.1245/s10434-008-9940-z]
87. Schneider G, Krämer OH, Fritsche P, Schüler S, Schmid RM, Saur D. Targeting histone deacetylases in pancreatic ductal adenocarcinoma. J Cell Mol Med 2010; 14: 1255-1263 [PMID: 19929947 DOI: 10.1111/j.1582-4934.2009.00974.x]
88. Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD, Friess H, Büchler M, Evert M, Lerch MM, Weiss FU. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregu-lates E-cadherin expression in pancreatic cancer. Gut 2012; 61: 439-448 [PMID: 22147512 DOI: 10.1136/gutjnl-2011-300060]
89. Schneider G, Krämer OH, Saur D. A ZEB1-HDAC pathway enters the epithelial to mesenchymal transition world in pancreatic cancer. Gut 2012; 61: 329-330 [PMID: 22147511 DOI: 10.1136/gutjnl-2011-301576]
90. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, Schnieke A, Schmid RM, Schneider G, Saur D. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastro-enterology 2009; 137: 361-71, 371.e1-5 [PMID: 19362090 DOI: 10.1053/j.gastro.2009.04.004]
91. Crea F, Paolicchi E, Marquez VE, Danesi R. Polycomb genes and cancer: time for clinical application? Crit Rev Oncol Hema-tol 2012; 83: 184-193 [PMID: 22112692 DOI: 10.1016/j.critrevo nc.2011.10.007]
92. Martínez-Romero C, Rooman I, Skoudy A, Guerra C, Molero X, González A, Iglesias M, Lobato T, Bosch A, Barbacid M, Real FX, Hernández-Muñoz I. The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol 2009; 219: 205-213 [PMID: 19585519 DOI: 10.1002/path.2585]
93. Song W, Tao K, Li H, Jin C, Song Z, Li J, Shi H, Li X, Dang Z, Dou K. Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 2010; 101: 1754-1760 [PMID: 20426791 DOI: 10.1111/j.1349-7006.2010.01577.x]
94. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-1495 [PMID: 19935649 DOI: 10.1038/ncb1998]
95. Karamitopoulou E, Pallante P, Zlobec I, Tornillo L, Carafa V, Schaffner T, Borner M, Diamantis I, Esposito F, Brunner T, Zimmermann A, Federico A, Terracciano L, Fusco A. Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer 2010; 46: 1438-1444 [PMID: 20185297 DOI: 10.1016/j.ejca.2010.01.033]
96. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008; 14: 6790-6796 [PMID: 18980972 DOI: 10.1158/1078-0432.CCR-08-1013]
97. Toll AD, Dasgupta A, Potoczek M, Yeo CJ, Kleer CG, Brody JR, Witkiewicz AK. Implications of enhancer of zeste homo-logue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol 2010; 41: 1205-1209 [PMID: 20573371 DOI: 10.1016/ j.humpath.2010.03.004]
98. Fujii S, Ito K, Ito Y, Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 2008; 283: 17324-17332 [PMID: 18430739 DOI: 10.1074/jbc.M800224200]
99. Nomoto S, Kinoshita T, Mori T, Kato K, Sugimoto H, Kana-zumi N, Takeda S, Nakao A. Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer. Br J Cancer 2008; 98: 1690-1695 [PMID: 18475302 DOI: 10.1038/sj.bjc.6604333]
100. Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, Chen Y. Enhancer of zeste homo-log 2 silences microRNA-218 in human pancreatic ductal ad-enocarcinoma cells by inducing formation of heterochroma-tin. Gastroenterology 2013; 144: 1086-1097.e9 [PMID: 23395645 DOI: 10.1053/j.gastro.2013.01.058]
101. Qazi AM, Gruzdyn O, Semaan A, Seward S, Chamala S, Dhulipala V, Sethi S, Ali-Fehmi R, Philip PA, Bouwman DL, Weaver DW, Gruber SA, Batchu RB. Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery 2012; 152: 704-11; discussion 711-3 [PMID: 22943841 DOI: 10.1016/j.surg.2012.07.020]
102. Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ, Giovannetti E. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther 2012; 11: 1735-1746 [PMID: 22622284 DOI: 10.1158/1535-7163.MCT-12-0037]
103. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell 2011; 19: 86-100 [PMID: 21215703 DOI: 10.1016/j.ccr.2010.10.035]
104. Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, Konuma T, Tanaka S, Tada M, Kanai F, Imazeki F, Iwama A, Yokosuka O. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012; 130: 2557-2567 [PMID: 21717453 DOI: 10.1002/ijc.26264]
105. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Mar-quez VE, Danesi R, Farrar WL. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer 2011; 10: 40 [PMID: 21501485 DOI: 10.1186/1476-4598-10-40]
106. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB, Brown R. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011; 10: 325-335 [PMID: 21216927 DOI: 10.1158/1535-7163.MCT-10-0788]
107. Stefansson OA, Esteller M. EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells. Breast Cancer Res 2011; 13: 309 [PMID: 21672285 DOI: 10.1186/bcr2871]
108. van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE, Hurt EM. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl Med 2013; 2: 43-52 [PMID: 23283488 DOI: 10.5966/sctm.2012-0036]
109. Dorado J, Lonardo E, Miranda-Lorenzo I, Heeschen C. Pancreatic cancer stem cells: new insights and perspectives. J Gastroenterol 2011; 46: 966-973 [PMID: 21698355 DOI: 10.1007/ s00535-011-0422-x]
110. Li C, Lee CJ, Simeone DM. Identifcation of human pancreatic cancer stem cells. Methods Mol Biol 2009; 568: 161-173 [PMID: 19582426 DOI: 10.1007/978-1-59745-280-9_10]
111. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol 2011; 223: 147-161 [PMID: 21125672 DOI: 10.1002/path.2793]
112. Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 2011; 118: 2830-2839 [PMID: 21734239 DOI: 10.1182/blood-2010-07-294827]
113. Merchant AA, Matsui W. Targeting Hedgehog--a cancer stem cell pathway. Clin Cancer Res 2010; 16: 3130-3140 [PMID: 20530699 DOI: 10.1158/1078-0432.CCR-09-2846]
114. Chun SG, Zhou W, Yee NS. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther 2009; 8: 1328-1339 [PMID: 19421011]
115. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 2011; 6: e24099 [PMID: 21909380 DOI: 10.1371/jour-nal.pone.0024099]
116. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, Chen C. Profling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg 2009; 33: 698-709 [PMID: 19030927 DOI: 10.1007/ s00268-008-9833-0]
117. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM. MicroRNA expression patterns to differentiate pancreatic adenocar-cinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901-1908 [PMID: 17473300 DOI: 10.1001/ jama.297.17.1901]
118. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Magh-nouj A, Labourier E, Hahn SA. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26: 4442-4452 [PMID: 17237814 DOI: 10.1038/sj.onc.1210228]
119. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120: 1046-1054 [PMID: 17149698 DOI: 10.1002/ijc.22394]
120. Park JY, Helm J, Coppola D, Kim D, Malafa M, Kim SJ. Mi-croRNAs in pancreatic ductal adenocarcinoma. World J Gas-troenterol 2011; 17: 817-827 [PMID: 21412491 DOI: 10.3748/ wjg.v17.i7.817]
121. Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J, Zhou J, Wu J, Shao C. Downregulation of miR-132 by promoter methyla-tion contributes to pancreatic cancer development. Carcino-genesis 2011; 32: 1183-1189 [PMID: 21665894 DOI: 10.1093/ carcin/bgr105]
122. Fukushige S, Horii A. Road to early detection of pancreatic cancer: Attempts to utilize epigenetic biomarkers. Cancer Lett 2014; 342: 231-237 [PMID: 22450751 DOI: 10.1016/ j.canlet.2012.03.022]
123. Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, Mullendore ME, Goggins MG, Hong SM, Maitra A. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009; 8: 340-346 [PMID: 19106647]
124. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009; 2: 807-813 [PMID: 19723895 DOI: 10.1158/1940-6207.CAPR-09-0094]
125. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S, Shiozaki A, Ikoma H, Okamoto K, Ochiai T, Taniguchi H, Otsuji E. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 2013; 108: 361-369 [PMID: 23329235 DOI: 10.1038/bjc.2012.546]
126. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y, Zhang CY. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58: 610-618 [PMID: 22194634 DOI: 10.1373/ clinchem.2011.172767]
127. Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H, Konishi H, Shiozaki A, Ikoma H, Okamoto K, Ochiai T, Taniguchi H, Otsuji E. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011; 105: 1733-1740 [PMID: 22045190 DOI: 10.1038/bjc.2011.453]
128. Kong X, Du Y, Wang G, Gao J, Gong Y, Li L, Zhang Z, Zhu J, Jing Q, Qin Y, Li Z. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci 2011; 56: 602-609 [PMID: 20614181 DOI: 10.1007/s10620-010-1285-3]
129. Farrell JJ, Toste P, Wu N, Li L, Wong J, Malkhassian D, Tran LM, Wu X, Li X, Dawson D, Wu H, Donahue TR. Endoscopi-cally acquired pancreatic cyst fuid microRNA 21 and 221 are associated with invasive cancer. Am J Gastroenterol 2013; 108: 1352-1359 [PMID: 23752880 DOI: 10.1038/ajg.2013.167]
130. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60: 2002-2006 [PMID: 10766191]
131. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specifc oligonucleotide hybridization. Am J Pathol 1993; 143: 545-554 [PMID: 8342602]
132. Rachakonda PS, Bauer AS, Xie H, Campa D, Rizzato C, Can-zian F, Beghelli S, Greenhalf W, Costello E, Schanne M, Heller A, Scarpa A, Neoptolemos JP, Werner J, Büchler M, Hoheisel JD, Hemminki K, Giese N, Kumar R. Somatic mutations in exocrine pancreatic tumors: association with patient survival. PLoS One 2013; 8: e60870 [PMID: 23565280 DOI: 10.1371/jour-nal.pone.0060870]
133. Zhong W, Chen W, Zhang D, Sun J, Li Y, Zhang J, Gao Y, Zhou W, Li S. CXCL12/CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: A clinical study. Exp Ther Med 2012; 4: 363-369 [PMID: 23181100 DOI: 10.3892/etm.2012.631]
134. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offer-haus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogel-stein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011; 333: 425 [PMID: 21719641 DOI: 10.1126/ science.1207313]
135. Sivaprasad S, Govardhan B, Harithakrishna R, Venkat Rao G, Pradeep R, Kunal B, Ramakrishna N, Anuradha S, Reddy DN. Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma. Pancreatology 2013; 13: 267-272 [PMID: 23719599 DOI: 10.1016/j.pan.2013.02.006]
136. Sun CY, Wang BL, Hu CQ, Peng RY, Gao YB, Gu QY, Wang DW. Expression of the bcl-2 gene and its signifcance in human pancreatic carcinoma. Hepatobiliary Pancreat Dis Int 2002; 1: 306-308 [PMID: 14612291]
137. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-3610 [PMID: 20606093 DOI: 10.1200/JCO.2009.25.7550]
138. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622 [PMID: 20606091 DOI: 10.1200/JCO.2010.28.1386]
139. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gall-inger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gem-citabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966 [PMID: 17452677 DOI: 10.1200/JCO.2006.07.9525]
140. Stintzing S, Kemmerling R, Kiesslich T, Alinger B, Ocker M, Neureiter D. Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? J Biomed Biotechnol 2011; 2011: 214143 [PMID: 21629744 DOI: 10.1155/2011/214143]
141. Schneider-Stock R, Ocker M. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs 2007; 10: 557-561 [PMID: 17665331]
142. Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 2013; 33: 2989-2996 [PMID: 23898051]
143. Neureiter D, Zopf S, Leu T, Dietze O, Hauser-Kronberger C, Hahn EG, Herold C, Ocker M. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 2007; 42: 103-116 [PMID: 17190770 DOI: 10.1080/00365520600874198]
144. Ocker M. Deacetylase inhibitorsfocus on non-histone targets and effects. World J Biol Chem 2010; 1: 55-61 [PMID: 21540990 DOI: 10.4331/wjbc.v1.i5.55]
145. Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer 2010; 116: 4670-4676 [PMID: 20597137 DOI: 10.1002/cncr.25414]
146. Marcu MG, Jung YJ, Lee S, Chung EJ, Lee MJ, Trepel J, Neck-ers L. Curcumin is an inhibitor of p300 histone acetylatrans-ferase. Med Chem 2006; 2: 169-174 [PMID: 16787365]
147. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnu-makkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-4499 [PMID: 18628464 DOI: 10.1158/1078-0432.CCR-08-0024]
148. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 2013; 14: 765-780 [PMID: 24105274 DOI: 10.1038/ nrg3554]
149. Xue Y, Abou Tayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth RJ, Suriawinata AA, Tsongalis GJ. Mi-croRNAs as diagnostic markers for pancreatic ductal adeno-carcinoma and its precursor, pancreatic intraepithelial neoplasm. Cancer Genet 2013; 206: 217-221 [PMID: 23933230 DOI: 10.1016/j.cancergen.2013.05.020]
150. Khan S, Ansarullah D, Jaggi M, Chauhan SC. Targeting microRNAs in pancreatic cancer: microplayers in the big game. Cancer Res 2013; 73: 6541-6547 [PMID: 24204026 DOI: 10.1158/0008-5472.CAN-13-1288]
151. Pai P, Rachagani S, Are C, Batra SK. Prospects of miRNA-based therapy for pancreatic cancer. Curr Drug Targets 2013; 14: 1101-1109 [PMID: 23834151]
152. Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG, Herold C. The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol 2007; 31: 567-576 [PMID: 17671683]
153. Adsay NV, Pierson C, Sarkar F, Abrams J, Weaver D, Conlon KC, Brennan MF, Klimstra DS. Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol 2001; 25: 26-42 [PMID: 11145249]
154. Brody JR, Costantino CL, Potoczek M, Cozzitorto J, McCue P, Yeo CJ, Hruban RH, Witkiewicz AK. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocar-cinoma. Mod Pathol 2009; 22: 651-659 [PMID: 19270646 DOI: 10.1038/modpathol.2009.15]
155. Hoorens A, Prenzel K, Lemoine NR, Klöppel G. Undiffer-entiated carcinoma of the pancreas: analysis of intermediate flament profle and Ki-ras mutations provides evidence of a ductal origin. J Pathol 1998; 185: 53-60 [PMID: 9713360 DOI: 10.1002/(SICI)1096-9896(199805)185:]
156. Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE, Yeo CJ, Hruban RH, Goggins M. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepi-thelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 2002; 160: 1573-1581 [PMID: 12000709 DOI: 10.1016/ S0002-9440(10)61104-2]
157. Hong SM, Kelly D, Griffth M, Omura N, Li A, Li CP, Hru-ban RH, Goggins M. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol 2008; 21: 1499-1507 [PMID: 18820670 DOI: 10.1038/modpathol.2008.157]
158. Kim SG, Wu TT, Lee JH, Yun YK, Issa JP, Hamilton SR, Rashid A. Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. Mod Pathol 2003; 16: 1086-1094 [PMID: 14614047 DOI: 10.1097/01.MP.0000094088.37888.A6]
159. Sato N, Fukushima N, Hruban RH, Goggins M. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol 2008; 21: 238-244 [PMID: 18157091 DOI: 10.1038/ modpathol.3800991]
160. Sato N, Fukushima N, Matsubayashi H, Iacobuzio-Donahue CA, Yeo CJ, Goggins M. Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer 2006; 107: 251-257 [PMID: 16752411 DOI: 10.1002/cncr.21977]
161. Sato N, Ueki T, Fukushima N, Iacobuzio-Donahue CA, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Aberrant methyla-tion of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2002; 123: 365-372 [PMID: 12105864]
162. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Ampli-fcation and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998; 21: 81-86 [PMID: 9496907]
163. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR. Amplifcation of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-3641 [PMID: 8622988]
164. Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH, Kern SE. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003; 163: 1255-1260 [PMID: 14507635 DOI: 10.1016/S0002-9440(10)63485-2]
165. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32 [PMID: 7726912 DOI: 10.1038/ng0994-27]
166. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-3130 [PMID: 9242437]
167. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Klöppel G, Kalthoff H, Ungefroren H, Löhr M, Scarpa A. Genetic profle of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Vir-chows Arch 2001; 439: 798-802 [PMID: 11787853]
168. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54: 3025-3033 [PMID: 8187092]
169. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534-1543 [PMID: 8494051]
170. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, Kern SE. Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res 2004; 10: 1597-1604 [PMID: 15014009]
171. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353 [PMID: 8553070]
172. Goggins M, Offerhaus GJ, Hilgers W, Griffn CA, Shekher M, Tang D, Sohn TA, Yeo CJ, Kern SE, Hruban RH. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopa-thology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 1998; 152: 1501-1507 [PMID: 9626054]
173. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56: 5360-5364 [PMID: 8968085]
174. Su GH, Hruban RH, Bansal RK, Bova GS, Tang DJ, Shekher MC, Westerman AM, Entius MM, Goggins M, Yeo CJ, Kern SE. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999; 154: 1835-1840 [PMID: 10362809 DOI: 10.1016/ S0002-9440(10)65440-5]
175. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarci-nomas. Cancer Res 1998; 58: 5329-5332 [PMID: 9850059]
176. Su GH, Hilgers W, Shekher MC, Tang DJ, Yeo CJ, Hruban RH, Kern SE. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998; 58: 2339-2342 [PMID: 9622070]
177. Teng DH, Perry WL, Hogan JK, Baumgard M, Bell R, Berry S, Davis T, Frank D, Frye C, Hattier T, Hu R, Jammulapati S, Ja-necki T, Leavitt A, Mitchell JT, Pero R, Sexton D, Schroeder M, Su PH, Swedlund B, Kyriakis JM, Avruch J, Bartel P, Wong AK, Tavtigian SV. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997; 57: 4177-4182 [PMID: 9331070]
178. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm BO, Pfeifer GP, Hoang-Vu C. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003; 22: 3806-3812 [PMID: 12802288 DOI: 10.1038/sj.onc.1206582]
179. Omura N, Li CP, Li A, Hong SM, Walter K, Jimeno A, Hidalgo M, Goggins M. Genome-wide profling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther 2008; 7: 1146-1156 [PMID: 18535405]
180. Thu KL, Radulovich N, Becker-Santos DD, Pikor LA, Pusic A, Lockwood WW, Lam WL, Tsao MS. SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling. Oncogene 2014; 33: 279-288 [PMID: 23318427 DOI: 10.1038/onc.2012.595]
181. Waraya M, Yamashita K, Katoh H, Ooki A, Kawamata H, Nishimiya H, Nakamura K, Ema A, Watanabe M. Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesis. BMC Cancer 2012; 12: 397 [PMID: 22958219 DOI: 10.1186/1471-2407-12-397]
182. Chang VH, Chu PY, Peng SL, Mao TL, Shan YS, Hsu CF, Lin CY, Tsai KK, Yu WC, Ch'ang HJ. Krüppel-like factor 10 expression as a prognostic indicator for pancreatic adenocar-cinoma. Am J Pathol 2012; 181: 423-430 [PMID: 22688058 DOI: 10.1016/j.ajpath.2012.04.025]
183. Li M, Zhao ZW. Clinical implications of mismatched repair gene promoter methylation in pancreatic cancer. Med Oncol 2012; 29: 970-976 [PMID: 21660619 DOI: 10.1007/s12032-011-9968-y]
184. Vogt M, Munding J, Grüner M, Liffers ST, Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A, Hermeking H. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 2011; 458: 313-322 [PMID: 21225432 DOI: 10.1007/s00428-010-1030-5]
185. Gao J, Song J, Huang H, Li Z, Du Y, Cao J, Li M, Lv S, Lin H, Gong Y. Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer. J Exp Clin Cancer Res 2010; 29: 28 [PMID: 20338068 DOI: 10.1186/1756-9966-29-28]
186. Brune K, Hong SM, Li A, Yachida S, Abe T, Griffth M, Yang D, Omura N, Eshleman J, Canto M, Schulick R, Klein AP, Hruban RH, Iacobuzio-Donohue C, Goggins M. Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev 2008; 17: 3536-3542 [PMID: 19064568 DOI: 10.1158/1055-9965.EPI-08-0630]
187. Bu XM, Zhao CH, Zhang N, Gao F, Lin S, Dai XW. Hyper-methylation and aberrant expression of secreted frizzled-re-lated protein genes in pancreatic cancer. World J Gastroenterol 2008; 14: 3421-3424 [PMID: 18528941]
188. Zhang L, Gao J, Li Z, Gong Y. Neuronal pentraxin II (NPTX2) is frequently down-regulated by promoter hypermethylation in pancreatic cancers. Dig Dis Sci 2012; 57: 2608-2614 [PMID: 22806544 DOI: 10.1007/s10620-012-2202-8]
189. Khursheed M, Kolla JN, Kotapalli V, Gupta N, Gowrishankar S, Uppin SG, Sastry RA, Koganti S, Sundaram C, Pollack JR, Bashyam MD. ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines. Br J Cancer 2013; 108: 2056-2062 [PMID: 23660946 DOI: 10.1038/bjc.2013.200]
190. Zhang L, Gao J, Li L, Li Z, Du Y, Gong Y. The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro. Mol Biol Rep 2011; 38: 4903-4911 [PMID: 21161403 DOI: 10.1007/s11033-010-0632-y]
191. Gu YM, Ma YH, Zhao WG, Chen J. Dickkopf3 overexpres-sion inhibits pancreatic cancer cell growth in vitro. World J Gastroenterol 2011; 17: 3810-3817 [PMID: 21987623 DOI: 10.3748/wjg.v17.i33.3810]
192. Ito T, Murata M, Tanaka S, Hirata K, Sawada N. Transcriptional regulation of claudin-18 via specifc protein kinase C signaling pathways and modifcation of DNA meth-ylation in human pancreatic cancer cells. J Cell Biochem 2011; 112: 1761-1772 [PMID: 21381080 DOI: 10.1002/jcb.23095]
193. Cai HH, Sun YM, Miao Y, Gao WT, Peng Q, Yao J, Zhao HL. Aberrant methylation frequency of TNFRSF10C promoter in pancreatic cancer cell lines. Hepatobiliary Pancreat Dis Int 2011; 10: 95-100 [PMID: 21269942]
194. Yao F, Sun M, Dong M, Jing F, Chen B, Xu H, Wang S. NPTX2 hypermethylation in pure pancreatic juice predicts pancreatic neoplasms. Am J Med Sci 2013; 346: 175-180 [PMID: 23360791 DOI: 10.1097/MAJ.0b013e31827b94b6]
195. Kato N, Yamamoto H, Adachi Y, Ohashi H, Taniguchi H, Suzuki H, Nakazawa M, Kaneto H, Sasaki S, Imai K, Shinomura Y. Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids. World J Gastroen-terol 2013; 19: 1718-1727 [PMID: 23555160 DOI: 10.3748/wjg. v19.i11.1718]
196. Rosty C, Geradts J, Sato N, Wilentz RE, Roberts H, Sohn T, Cameron JL, Yeo CJ, Hruban RH, Goggins M. p16 Inactiva-tion in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol 2003; 27: 1495-1501 [PMID: 14657708]
197. Hong SM, Omura N, Vincent A, Li A, Knight S, Yu J, Hru-ban RH, Goggins M. Genome-wide CpG island profling of intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 2012; 18: 700-712 [PMID: 22173550 DOI: 10.1158/1078-0432.CCR-11-1718]
198. Park JK, Ryu JK, Lee KH, Lee JK, Yoon WJ, Lee SH, Yoo JW, Woo SM, Lee GY, Lee CH, Kim YT, Yoon YB. Quantitative analysis of NPTX2 hypermethylation is a promising molecular diagnostic marker for pancreatic cancer. Pancreas 2007; 35: e9-15 [PMID: 17895837 DOI: 10.1097/MPA.0b013e318153fa42]
199. Park JK, Ryu JK, Yoon WJ, Lee SH, Lee GY, Jeong KS, Kim YT, Yoon YB. The role of quantitative NPTX2 hypermethyl-ation as a novel serum diagnostic marker in pancreatic cancer. Pancreas 2012; 41: 95-101 [PMID: 21778928 DOI: 10.1097/ MPA.0b013e318221c903]
200. Chen M, Xue X, Wang F, An Y, Tang D, Xu Y, Wang H, Yuan Z, Gao W, Wei J, Zhang J, Miao Y. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. Oncol Rep 2012; 27: 265-269 [PMID: 21956451 DOI: 10.3892/or.2011.1475]
201. Weiss FU, Marques IJ, Woltering JM, Vlecken DH, Aghdassi A, Partecke LI, Heidecke CD, Lerch MM, Bagowski CP. Reti-noic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterol-ogy 2009; 137: 2136-45.e1-7 [PMID: 19747919 DOI: 10.1053/ j.gastro.2009.08.065]
202. Ohuchida K, Mizumoto K, Lin C, Yamaguchi H, Ohtsuka T, Sato N, Toma H, Nakamura M, Nagai E, Hashizume M, Tanaka M. MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene. Ann Surg Oncol 2012; 19: 2394-2402 [PMID: 22407312 DOI: 10.1245/s10434-012-2252-3]
203. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T, Takahata S, Toma H, Nagai E, Tanaka M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009; 8: 1067-1074 [PMID: 19435867 DOI: 10.1158/1535-7163.MCT-08-0592]
204. Zhang S, Cai X, Huang F, Zhong W, Yu Z. Effect of tricho-statin a on viability and microRNA expression in human pancreatic cancer cell line BxPC-3. Exp Oncol 2008; 30: 265-268 [PMID: 19112422]
205. Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic ad-enocarcinoma. Pancreas 2009; 38: e190-e199 [PMID: 19730150 DOI: 10.1097/MPA.0b013e3181ba82e1]
206. Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Post-ier RG, Brackett DJ, Schmittgen TD. miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun 2011; 406: 518-523 [PMID: 21329664 DOI: 10.1016/j.bbrc.2011.02.065]
207. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gom-meaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A, Gleave M, Dagorn JC, Iovanna JL, Carrier A, Pébusque MJ, Dusetti NJ. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007; 104: 16170-16175 [PMID: 17911264 DOI: 10.1073/pnas.0703942104]
208. Mees ST, Mardin WA, Wendel C, Baeumer N, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J. EP300--a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer 2010; 126: 114-124 [PMID: 19569050 DOI: 10.1002/ijc.24695]
209. Hamada S, Satoh K, Miura S, Hirota M, Kanno A, Masamune A, Kikuta K, Kume K, Unno J, Egawa S, Motoi F, Unno M, Shimosegawa T. miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol 2013; 228: 1255-1263 [PMID: 23139153 DOI: 10.1002/jcp.24280]
210. Takikawa T, Masamune A, Hamada S, Nakano E, Yoshida N, Shimosegawa T. miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Biochem Biophys Res Commun 2013; 437: 433-439 [PMID: 23831622 DOI: 10.1016/ j.bbrc.2013.06.097]
211. Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 2009; 16: 2339-2350 [PMID: 19475450 DOI: 10.1245/s10434-009-0531-4]
212. Chen Z, Chen LY, Dai HY, Wang P, Gao S, Wang K. miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression. J Cell Biochem 2012; 113: 3229-3235 [PMID: 22628193 DOI: 10.1002/jcb.24200]
213. Iwagami Y, Eguchi H, Nagano H, Akita H, Hama N, Wada H, Kawamoto K, Kobayashi S, Tomokuni A, Tomimaru Y, Mori M, Doki Y. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer 2013; 109: 502-511 [PMID: 23799850 DOI: 10.1038/bjc.2013.320]
214. Hao J, Zhang S, Zhou Y, Liu C, Hu X, Shao C. MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer. Biochem Biophys Res Commun 2011; 406: 552-557 [PMID: 21352803 DOI: 10.1016/j.bbrc.2011.02.086]
215. Guo R, Wang Y, Shi WY, Liu B, Hou SQ, Liu L. MicroRNA miR-491-5p targeting both TP53 and Bcl-XL induces cell apoptosis in SW1990 pancreatic cancer cells through mitochondria mediated pathway. Molecules 2012; 17: 14733-14747 [PMID: 23519249 DOI: 10.3390/molecules171214733]
216. Torrisani J, Bournet B, du Rieu MC, Bouisson M, Souque A, Escourrou J, Buscail L, Cordelier P. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009; 20: 831-844 [PMID: 19323605 DOI: 10.1089/ hum.2008.134]
217. Oh JS, Kim JJ, Byun JY, Kim IA. Lin28-let7 modulates radio-sensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys 2010; 76: 5-8 [PMID: 20005451 DOI: 10.1016/j.ijrobp.2009.08.028]
218. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 2008; 7: 464-473 [PMID: 18347134 DOI: 10.1158/1535-7163.MCT-07-2272]
219. Li W, Yuan Y, Huang L, Qiao M, Zhang Y. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 2012; 96: 187-195 [PMID: 22245693 DOI: 10.1016/j.diabres.2011.12.028]
220. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, De-sano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS, Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009; 4: e6816 [PMID: 19714243 DOI: 10.1371/journal.pone.0006816]
221. Hu QL, Jiang QY, Jin X, Shen J, Wang K, Li YB, Xu FJ, Tang GP, Li ZH. Cationic microRNA-delivering nanovectors with bifunctional peptides for effcient treatment of PANC-1 xeno-graft model. Biomaterials 2013; 34: 2265-2276 [PMID: 23298779 DOI: 10.1016/j.biomaterials.2012.12.016]
222. Xia J, Duan Q, Ahmad A, Bao B, Banerjee S, Shi Y, Ma J, Geng J, Chen Z, Rahman KM, Miele L, Sarkar FH, Wang Z. Genis-tein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Curr Drug Targets 2012; 13: 1750-1756 [PMID: 23140286]
223. Liu C, Cheng H, Shi S, Cui X, Yang J, Chen L, Cen P, Cai X, Lu Y, Wu C, Yao W, Qin Y, Liu L, Long J, Xu J, Li M, Yu X. MicroR-NA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med 2013; 13: 467-478 [PMID: 23305226]
224. Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, Goggins MG, Mendell JT, Maitra A. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009; 9: 293-301 [PMID: 19407485 DOI: 10.1159/000186051]
225. Hamada S, Satoh K, Fujibuchi W, Hirota M, Kanno A, Unno J, Masamune A, Kikuta K, Kume K, Shimosegawa T. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res 2012; 10: 3-10 [PMID: 22064652 DOI: 10.1158/1541-7786.MCR-11-0272]
226. Pham H, Rodriguez CE, Donald GW, Hertzer KM, Jung XS, Chang HH, Moro A, Reber HA, Hines OJ, Eibl G. miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. Biochem Biophys Res Commun 2013; 439: 6-11 [PMID: 23973710 DOI: 10.1016/j.bbrc.2013.08.042]
227. Hu Y, Ou Y, Wu K, Chen Y, Sun W. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumour Biol 2012; 33: 1863-1870 [PMID: 23070684 DOI: 10.1007/s13277-012-0446-8]
228. Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, Maghnouj A, Mirmohammadsadegh A, Hahn SA, Tannapfel A. MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Invest 2011; 91: 1472-1479 [PMID: 21709669 DOI: 10.1038/labinvest.2011.99]
229. Zhao G, Zhang JG, Liu Y, Qin Q, Wang B, Tian K, Liu L, Li X, Niu Y, Deng SC, Wang CY. miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Mol Cancer Ther 2013; 12: 83-93 [PMID: 23171948 DOI: 10.1158/1535-7163.MCT-12-0534-T]
230. Srivastava SK, Bhardwaj A, Singh S, Arora S, Wang B, Grizzle WE, Singh AP. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis 2011; 32: 1832-1839 [PMID: 21983127 DOI: 10.1093/carcin/bgr223]
231. Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712 [PMID: 19654291 DOI: 10.1158/0008-5472.CAN-09-1298]
232. Zhou J, Song S, Cen J, Zhu D, Li D, Zhang Z. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Oncol Res 2012; 20: 197-203 [PMID: 23581226]
233. Heyn H, Schreek S, Buurman R, Focken T, Schlegelberger B, Beger C. MicroRNA miR-548d is a superior regulator in pancreatic cancer. Pancreas 2012; 41: 218-221 [PMID: 21946813 DOI: 10.1097/MPA.0b013e318224b701]
234. Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom ST, Mc-Conkey DJ, Palladino MA, Spear MA. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs 2012; 30: 2303-2317 [PMID: 22080430 DOI: 10.1007/s10637-011-9766-6]
235. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 2012; 106: 77-84 [PMID: 22134508 DOI: 10.1038/bjc.2011.527]
236. Wang H, Cao Q, Dudek AZ. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res 2012; 32: 1027-1031 [PMID: 22399627]
237. Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol 2013; 71: 1521-1530 [PMID: 23543271 DOI: 10.1007/s00280-013-2151-8]
238. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010; 62: 1137-1141 [PMID: 21058202 DOI: 10.1080/01635581.2010.513802]
239. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, Aggarwal BB. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011; 68: 157-164 [PMID: 20859741 DOI: 10.1007/s00280-010-1470-2]